Meeder Asset Management Inc. Lowers Stake in Zoetis Inc. $ZTS

Meeder Asset Management Inc. reduced its stake in shares of Zoetis Inc. (NYSE:ZTS) by 93.8% in the second quarter, HoldingsChannel.com reports. The fund owned 2,789 shares of the company’s stock after selling 42,497 shares during the quarter. Meeder Asset Management Inc.’s holdings in Zoetis were worth $200,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. Louisiana State Employees Retirement System purchased a new position in shares of Zoetis during the first quarter worth approximately $2,542,000. Deutsche Bank AG boosted its stake in shares of Zoetis by 19.1% in the 4th quarter. Deutsche Bank AG now owns 5,558,183 shares of the company’s stock valued at $699,331,000 after purchasing an additional 891,921 shares in the last quarter. Pincus Capital Management LP purchased a new stake in shares of Zoetis in the 4th quarter valued at $2,109,000. Diamond Hill Capital Management LLC Investment Advisor grew its holdings in shares of Zoetis by 21.5% during the 2nd quarter. Diamond Hill Capital Management LLC Investment Advisor now owns 3,557,436 shares of the company’s stock valued at $255,637,000 after purchasing an additional 629,974 shares during the last quarter. Finally, Highbridge Capital Management LLC purchased a new position in Zoetis in the 4th quarter worth $7,004,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of Zoetis stock opened at $76.78 on Thursday. The firm has a market cap of $31.73 billion, a PE ratio of 12.65, a price-to-earnings-growth ratio of 1.73 and a beta of 0.74. Zoetis Inc. has a 12-month low of $71.00 and a 12-month high of $160.48. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. The company’s fifty day simple moving average is $75.92 and its two-hundred day simple moving average is $97.81.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.85 by $0.02. The firm had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company’s quarterly revenue was down .2% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities analysts expect that Zoetis Inc. will post 6.2 EPS for the current year.

Analyst Ratings Changes

Several research firms have weighed in on ZTS. TD Cowen lowered their price target on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating for the company in a research note on Tuesday, June 30th. Zacks Research downgraded Zoetis from a “hold” rating to a “strong sell” rating in a report on Monday, August 10th. Piper Sandler lowered their target price on Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, August 10th. UBS Group reduced their price target on Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a research report on Friday, August 7th. Finally, JPMorgan Chase & Co. decreased their price target on Zoetis from $130.00 to $115.00 and set an “overweight” rating on the stock in a research note on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $109.62.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.